Athenex to Acquire Kuur Therapeutics for ~$185M
Shots:
- Kuur will receive $70M up front primarily in Athenex common stock and is eligible to receive ~$115 M as a milestone at Athenex's sole discretion in either cash or additional Athenex common stock (or a combination of both)
- The acquisition will expand Athenex’s cell therapy development capability with Kuur’s off-the-shelf engineered CAR-NKT platform and allow the companies to combine CARs and TCRs with the NKT cell platform to target hematological and solid cancers- respectively
- The platform has the potential to provide synergies with other assets in Athenex’s pipeline
Ref: GLOBE NEWSWIRE | Image: Athenex
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com